114 related articles for article (PubMed ID: 30955254)
1. Arctigenin Inhibits Etoposide Resistance in HT-29 Colon Cancer Cells during Microenvironmental Stress.
Yoon SB; Park HR
J Microbiol Biotechnol; 2019 Apr; 29(4):571-576. PubMed ID: 30955254
[TBL] [Abstract][Full Text] [Related]
2. Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator.
Hwang JH; Kim JY; Cha MR; Ryoo IJ; Choo SJ; Cho SM; Tsukumo Y; Tomida A; Shin-Ya K; Hwang YI; Yoo ID; Park HR
J Cell Physiol; 2008 Apr; 215(1):243-50. PubMed ID: 17941090
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
4. The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase IIα and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
Cai Y; Zhao B; Liang Q; Zhang Y; Cai J; Li G
Eur J Pharmacol; 2017 Aug; 809():87-97. PubMed ID: 28506909
[TBL] [Abstract][Full Text] [Related]
5. Mithramycin inhibits etoposide resistance in glucose-deprived HT-29 human colon carcinoma cells.
Lee EM; Park HR; Hwang JH; Park DJ; Chang KS; Kim CJ
J Microbiol Biotechnol; 2007 Nov; 17(11):1856-61. PubMed ID: 18092471
[TBL] [Abstract][Full Text] [Related]
6. Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity.
Kim JY; Hwang JH; Cha MR; Yoon MY; Son ES; Tomida A; Ko B; Song SW; Shin-ya K; Hwang YI; Park HR
J Cell Physiol; 2010 Jul; 224(1):33-40. PubMed ID: 20232300
[TBL] [Abstract][Full Text] [Related]
7. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
8. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
11. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Gray MD; Mann M; Nitiss JL; Hendershot LM
Mol Pharmacol; 2005 Dec; 68(6):1699-707. PubMed ID: 16141312
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
14. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78.
Hsu JL; Chiang PC; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):373-82. PubMed ID: 19777212
[TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
16. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
Patel S; Keller BA; Fisher LM
Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Arctigenin induces apoptosis in colon cancer cells through ROS/p38MAPK pathway.
Li QC; Liang Y; Tian Y; Hu GR
J BUON; 2016; 21(1):87-94. PubMed ID: 27061535
[TBL] [Abstract][Full Text] [Related]
19. Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation.
Baba Y; Shigemi Z; Hara N; Moriguchi M; Ikeda M; Watanabe T; Fujimuro M
Int J Oncol; 2018 Feb; 52(2):505-517. PubMed ID: 29207179
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
